Health Care · Laboratory Analytical Instruments

PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1299130125 filings
Russell 2000

PACB at a glance

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB, SEC CIK 1299130) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported revenue of $160.0 million (up 3.9% from FY2024) and a net loss of $546.4 million. Diluted EPS was -$1.82.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) shares worth $307.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by ORDONEZ KATHY on November 17, 2026 of 18,595 shares at $1.78 per share.
  • In the last 90 days, PACB insiders reported 0 open-market purchases ($0) and 2 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$160.0M
+3.9% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$2.1M
13F holders
29 funds
$307.4M · −3 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 1.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $40.6M, up 6% YoY from $38.4M, driven by product revenue and services growth
  • Gross margin 33.2% vs 41.4% YoY, with gross profit down 15% to $13.5M
  • Instrument revenue up 16% to $13.9M, while consumables revenue declined 2% to $20.1M
  • Operating loss $37.0M, with operating margin negative 91.2% vs negative 101.1% YoY
  • Cash and investments $199.4M vs $279.5M at December 31, 2025; operating cash use $117.9M
  • Outlook: consumables growth expected, but funding constraints, memory costs and tariffs remain headwinds

Risk Factors

  • New asset-disposition risk: January 30, 2026 sale retained pre-closing liabilities tied to short-read sequencing technologies
  • New expense-reduction risk: third-quarter 2026 workforce reductions and development cuts may disrupt operations and produce higher-than-anticipated charges
  • Regulatory risk: BIOSECURE Act limits certain Chinese biotechnology equipment and services, potentially disrupting supply and commercialization
  • Near-term market risk: Revio and Vega adoption may lag as customers delay capital purchases amid uncertain academic and NIH funding
  • Financial risk: September 30, 2026 debt included $200.0 million due 2029 and $441.0 million due 2030 amid negative operating cash flow

AI summary of the PACB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Up to $100 million ATM equity capacity, providing PACB flexible access to capital without a committed issuance
  • Potential shareholder dilution, with issuance timing and volume controlled by the company
Filed Nov 4, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CFO Jim Gibson stepped down November 3, 2026, creating executive finance-transition risk
  • Gibson remains an advisor through March 31, 2027, retaining salary, 2026 bonus eligibility and equity vesting

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $40.6M, up from $38.4M, led by instrument revenue $13.2M versus $11.3M
  • Consumables revenue fell to $20.8M from $21.3M, while annualized Revio pull-through declined to ~$204,000 from ~$236,000
Filed Aug 5, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Mark Van Oene becomes CEO and director August 5, succeeding Christian Henry, who remains on the Board
  • CEO compensation: $743,000 salary, 100% target bonus, $1.6875M option, and $562,500 RSU award

Item EX-99.1: Item EX-99.1

  • Q2 revenue $39.0M, down from $39.8M; consumables rose to $20.1M while instrument revenue declined to $12.8M
  • Revio placements increased to 20 from 15, but Vega placements fell to 26 from 38 and annualized Revio pull-through declined to ~$202,000

Item 7.01: Regulation FD Disclosure

  • August 5, 2026 press release announces leadership changes described under Item 5.02
  • Leadership transition may affect PACB’s strategic execution and investor assessment of management continuity

Item 2.05: Costs Associated with Exit or Disposal Activities

  • Workforce reduction of approximately 40 employees, or 8% of staff
  • Annualized operating expense savings targeted at $30 million to $40 million by end-2027

Item EX-99.2: Item EX-99.2

  • Mark Van Oene appointed President and CEO effective August 5, 2026, succeeding Christian Henry after six years
  • Internal succession: Van Oene previously served as COO since 2021, reducing near-term leadership disruption risk

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results for quarter ended June 30, 2026 announced
  • Full financial results and management commentary available in Exhibit 99.1

AI summaries of PACB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PACB

Don't miss the next PACB filing

  • Alerts as it files. A push when PACB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PACB, by share count.
  • Ask anything. An AI agent that reads every PACB filing and answers with sources.

PACB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MEYER WILLIAMANov 17, 2026-
ORDONEZ KATHYSellNov 17, 2026$1.78
MEYER WILLIAMANov 17, 2026-
Gibson James R IIMOct 6, 2026-
Gibson James R IIMOct 6, 2026$1.18
Gibson James R IISellOct 6, 2026$3.11
Van Oene MarkSellAug 17, 2026$1.13
Van Oene MarkAAug 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$200.5M$154.0M$160.0M
Gross Profit-$37.3M$45.8M
Operating Income--$474.3M-$553.9M
Net Income--$309.9M-$546.4M
Gross Margin-24.2%28.6%
Op. Margin--308.0%-346.2%
Net Margin--201.2%-341.5%
Balance Sheet
Total Assets-$1.3B$784.1M
Equity$701.3M$506.6M$5.3M
ROE--61.2%-10214.5%
Per Share
EPS-$-1.59$-1.82
Cash Flow
Operating CF--$206.1M-$111.2M
CapEx-$6.2M$2.7M

Source: XBRL data in PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PACB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PACB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$307.4M
Q2 202632$190.0M
Q1 202630$146.2M
Q4 202528$213.8M
Q3 202529$118.9M
Q2 202528$111.4M
Q1 202527$88.7M
Q4 202421$161.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 224 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PACB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 19, 2026--
8-KNov 10, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 8, 2026--
4Aug 18, 2026--
4Aug 11, 2026--
10-QAug 6, 2026Analysis
8-KAug 5, 2026Analysis-
8-KJul 9, 2026Analysis-
4Jun 4, 2026-
4Jun 4, 2026-
8-KJun 4, 2026Analysis
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
10-QMay 8, 2026Analysis
8-KMay 7, 2026Analysis
4Apr 10, 2026--
4Apr 3, 2026--
8-KMar 6, 2026Analysis-

Related Health Care companies

All Health Care →

PACB SEC filings: frequently asked questions

Are PACB insiders buying or selling?

In the last 90 days, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $2.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold PACB stock?

As of September 30, 2026, the largest PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) holders among the 13F filers tracked by SignalX were BlackRock ($77.7 million), ARK Investment Management ($70.5 million), Vanguard Capital Management LLC ($31.4 million), T. Rowe Price Group ($25.9 million), D.E. Shaw & Co ($16.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PACB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported revenue of $160.0 million (up 3.9% from FY2024) and a net loss of $546.4 million. Diluted EPS was -$1.82. The figures come from the XBRL data in the 10-K.

What did PACB report in its latest 8-K?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an 8-K on November 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Up to $100 million ATM equity capacity, providing PACB flexible access to capital without a committed issuance.

What are the latest PACB SEC filings?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 19, 2026.

What is PACB's SEC CIK number?

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)'s SEC Central Index Key (CIK) is 1299130. EDGAR lists every PACB filing under that number.

Ask anything about PACB

The research agent reads PACB's filings, financials, insider trades and 13F holders, then answers with sources.